Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Clinical Data Clinical Trial Results 28.7% Average Weight Loss 68 weeks 58.6% Achieved 25%+ Loss of participants 445 Trial Participants Phase 3 Data from the Phase 3 TRIUMPH-4 trial of retatrutide, reported by Eli Lilly (topline, 2025)
Introduction On May 21, 2026, Eli Lilly announced the topline results of TRIUMPH-1 the pivotal Phase 3 trial that anchors retatrutide's case for FDA approval in obesity
We gaan in de weer met alle ingeleverde kwisboekjes
More frequently than standard Hashimoto's monitoring
US$ 22.93
US$ 25.22
US$ 21.78
US$ 23.18
